Microcap Ledger Allogene Therapeutics, Inc. $ALLO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
- Shares outstanding
- 345,490,881 [10-Q 2026-08-12]
What the company doesAI summary of filing
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic CAR T cell product candidates for treating cancer and autoimmune diseases. The company manufactures off-the-shelf T cells from healthy donors using gene-editing technologies, designed to be administered to any eligible patient rather than requiring individualized manufacturing. Allogene currently has no revenue and is focused on advancing three core programs: cema-cel for large B-cell lymphoma (in Phase 2 pivotal trial), ALLO-316 for renal cell carcinoma (Phase 1 completed), and ALLO-329 for autoimmune diseases including systemic lupus erythematosus (Phase 1 ongoing). The company generates potential future revenue through product development funded by additional capital, with multiple clinical readouts anticipated in the second quarter of 2026. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $4.64M | −$85.28M | −$44.91M | $38.63M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $0.00 | −$190.89M | −$149.25M | $51.69M | [10-K 2026-03-12] |
| FY ended Dec 2024 | $22.0K | −$257.59M | −$200.30M | $75.22M | [10-K 2026-03-12] |
- Quarterly cash burn
- −$22.45M
- Cash runway Estimate
- ~5.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 209,672,091 | [10-Q 2024-11-07] |
| 2025-03-07 | 217,264,738 | [10-K 2025-03-13] |
| 2025-05-09 | 218,730,809 | [10-Q 2025-05-13] |
| 2025-08-11 | 221,881,029 | [10-Q 2025-08-13] |
| 2025-11-04 | 224,730,144 | [10-Q 2025-11-06] |
| 2026-03-10 | 243,777,920 | [10-K 2026-03-12] |
| 2026-05-11 | 345,154,561 | [10-Q 2026-05-13] |
| 2026-08-10 | 345,490,881 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2026-08-12; declared effective 2026-08-20 [S-3 2026-08-12]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-21 | Douglas Earl Martin | sell | 29,697 | $2.12 | [4 2026-08-25] |
| 2026-06-18 | Kazam Joshua A | exercise | 47,700 | — | [4 2026-06-23] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-09-02 | 8-K | Director or officer change |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | S-3 | Registration statement |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations |
| 2026-08-07 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-22 | 8-K | Shareholder vote results; Other events |
| 2026-06-22 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-28 | 8-K | Director or officer change |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $ALLO
Email me when Allogene Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.